indication

For diagnosis of prostate cancer and detection of intra-pelvic metastases.

pharmacology

Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.

mechanism of action

Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.

biotransformation

Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production

route of elimination

Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.